Protagonist seeks an Ideal readout
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
Go or no go? Bristol's first-in-class hopes
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Significant readouts for small players
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Big pharma’s key second-quarter data
Roche awaits Tigit and Serd data, Lilly takes on obesity, and Glaxo and Pfizer race in RSV.
Biohaven’s high-risk bet
There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.
Glaxo holds its breath
A late-stage hit with its respiratory syncytial virus jab would be a huge validation for the group’s new focus.
Go or no go? Bristol’s Lag3 debut
March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.
Imara gets a second shot in sickle cell
Will upping the dose and changing the primary endpoint pay off?
